Baillie Gifford & Co
RXRX icon

Baillie Gifford & Co’s Recursion Pharmaceuticals RXRX Stock Holding History

Baillie Gifford & Co’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$86.2M Sell
23,487,907
-187,500
-0.8% -$624K 0.08% 143
2026
Q1 		$72.7M Sell
23,675,407
-99,565
-0.4% -$385K 0.07% 136
2025
Q4 		$97.2M Sell
23,774,972
-203,723
-0.8% -$1.01M 0.08% 127
2025
Q3 		$117M Sell
23,978,695
-195,120
-0.8% -$1.02M 0.09% 122
2025
Q2 		$122M Sell
24,173,815
-219,200
-0.9% -$1.08M 0.09% 122
2025
Q1 		$129M Sell
24,393,015
-471,043
-2% -$3.43M 0.11% 116
2024
Q4 		$168M Sell
24,864,058
-375,812
-1% -$2.53M 0.13% 110
2024
Q3 		$166M Sell
25,239,870
-1,350,066
-5% -$9.68M 0.12% 106
2024
Q2 		$199M Buy
26,589,936
+2,522,132
+10% +$22M 0.16% 95
2024
Q1 		$240M Sell
24,067,804
-111,700
-0.5% -$1.24M 0.19% 93
2023
Q4 		$238M Sell
24,179,504
-371,905
-2% -$2.65M 0.19% 98
2023
Q3 		$188M Sell
24,551,409
-546,221
-2% -$5.45M 0.17% 95
2023
Q2 		$187M Sell
25,097,630
-37,900
-0.2% -$265K 0.16% 101
2023
Q1 		$168M Buy
25,135,530
+314,680
+1% +$2.5M 0.15% 102
2022
Q4 		$191M Buy
24,820,850
+3,226,157
+15% +$31.6M 0.2% 92
2022
Q3 		$230M Sell
21,594,693
-10,992
-0.1% -$111K 0.24% 85
2022
Q2 		$176M Sell
21,605,685
-375,919
-2% -$2.52M 0.18% 94
2022
Q1 		$157M Sell
21,981,604
-141,551
-0.6% -$1.5M 0.11% 112
2021
Q4 		$379M Buy
22,123,155
+61,781
+0.3% +$1.16M 0.21% 88
2021
Q3 		$508M Buy
22,061,374
+3,540,374
+19% +$100M 0.27% 83
2021
Q2 		$676M Buy
+18,521,000
New +$548M 0.33% 79

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Baillie Gifford & Co's RXRX Position: Q2 2026 in Review

Baillie Gifford & Co reduced its Recursion Pharmaceuticals (RXRX) stake by 0.79% in Q2 2026, selling an estimated $624K and leaving 23,487,907 shares worth $86.2M. The position accounts for 0.08% of the portfolio, ranked #143.

Baillie Gifford & Co first reported a position in RXRX in Q2 2021 and has held it in 21 quarters since. The position peaked at $676M in Q2 2021. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Baillie Gifford & Co held 23,487,907 shares of Recursion Pharmaceuticals worth $86.2M as of Q2 2026.
  • Baillie Gifford & Co sold 187,500 Recursion Pharmaceuticals shares in Q2 2026, an estimated $624K.
  • Recursion Pharmaceuticals made up 0.08% of Baillie Gifford & Co's portfolio in Q2 2026, its #143 holding.
  • Baillie Gifford & Co first reported a position in Recursion Pharmaceuticals in Q2 2021 and has held it in 21 quarters since.
  • Baillie Gifford & Co's Recursion Pharmaceuticals position peaked at $676M in Q2 2021.
  • 342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Baillie Gifford & Co's 13F filing for Q2 2026, filed 6 Aug 2026.